NAUT
Nautilus Biotechnology, Inc.
1W: +30.0%
1M: +4.8%
3M: +62.9%
YTD: +58.6%
1Y: +215.6%
3Y: +37.1%
5Y: -79.4%
$3.03
+0.28 (+10.18%)
After Hours: $2.95 (-0.08, -2.81%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$4.1M
Congress—
ETF Holdings—
Key Statistics
Market Cap$383.5M
52W Range0.62-3.08
Volume481,705
Avg Volume204,611
Beta1.36
Dividend—
Analyst Ratings
Company Info
CEOSujal Patel
Employees134
SectorHealthcare
IndustryBiotechnology
IPO Date2020-08-07
Websitenautilus.bio
2701 Eastlake Avenue East
Seattle, WA 98102
US
Seattle, WA 98102
US
206 333 2001
About Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Latest News
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales
Nautilus projects 15%-20% expense growth in 2026 as early access program ramps up
Nautilus Biotechnology GAAP EPS of -$0.11 beats by $0.03
Nautilus Biotechnology, Inc. (NAUT) Q4 2025 Earnings Call Transcript
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Patel Sujal M | P-Purchase | 25,000 | $2.61 | 2026-03-04 |
| Mowry Anna | A-Award | 160,000 | $2.32 | 2026-03-02 |
| Mallick Parag | A-Award | 280,000 | $2.32 | 2026-03-02 |
| Patel Sujal M | A-Award | 650,000 | $2.32 | 2026-03-02 |
| Sankar Subramanian | A-Award | 160,000 | $2.32 | 2026-03-02 |